PMID- 33435244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210604
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 9
IP  - 1
DP  - 2021 Jan 10
TI  - Does Platelet-Rich Fibrin Enhance the Early Angiogenetic Potential of Different 
      Bone Substitute Materials? An In Vitro and In Vivo Analysis.
LID - 10.3390/biomedicines9010061 [doi]
LID - 61
AB  - The impaired angiogenic potential of bone substitute materials (BSMs) may limit 
      regenerative processes. Therefore, changes in the angiogenetic properties of 
      different BSMs in combination with platelet-rich fibrin (PRF) in comparison to 
      PRF alone, as well as to native BSMs, were analyzed in vitro and in vivo to 
      evaluate possible clinical application. In vitro, four BSMs of different origins 
      (allogeneic, alloplastic, and xenogeneic) were biofunctionalized with PRF and 
      compared to PRF in terms of platelet interaction and growth factor release 
      (vascular endothelial growth factor (VEGF), tissue growth factor ss (TGFss) and 
      platelet-derived growth factor (PDGF)) after 15 min. To visualize initial 
      cell-cell interactions, SEM was performed. In vivo, all BSMs (+/-PRF) were analyzed 
      after 24 h for new-formed vessels using a chorioallantoic membrane (CAM) assay. 
      Especially for alloplastic BSMs, the addition of PRF led to a significant 
      consumption of platelets (p = 0.05). PDGF expression significantly decreased in 
      comparison to PRF alone (all BSMs: p < 0.013). SEM showed the close spatial 
      relation of each BSM and PRF. In vivo, PRF had a significant positive 
      pro-angiogenic influence in combination with alloplastic (p = 0.007) and 
      xenogeneic materials (p = 0.015) in comparison to the native BSMs. For 
      bio-activated xenogeneic BSMs, the branching points were also significantly 
      increased (p = 0.005). Finally, vessel formation was increased for BSMs and PRF 
      in comparison to the native control (allogeneic: p = 0.046; alloplastic: p = 
      0.046; and xenogeneic: p = 0.050). An early enhancement of angiogenetic 
      properties was demonstrated when combining BSMs with PRF in vitro and led to 
      upregulated vessel formation in vivo. Thus, the use of BSMs in combination with 
      PRF may trigger bony regeneration in clinical approaches.
FAU - Blatt, Sebastian
AU  - Blatt S
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, 
      Augustusplatz 2, 55131 Mainz, Germany.
AD  - Platform for Biomaterial Research, BiomaTiCS Group, University Medical Center, 
      Langenbeckstrasse 1, 55131 Mainz, Germany.
FAU - Thiem, Daniel G E
AU  - Thiem DGE
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, 
      Augustusplatz 2, 55131 Mainz, Germany.
AD  - Platform for Biomaterial Research, BiomaTiCS Group, University Medical Center, 
      Langenbeckstrasse 1, 55131 Mainz, Germany.
FAU - Pabst, Andreas
AU  - Pabst A
AD  - Department of Oral and Maxillofacial Surgery, Federal Armed Forces Hospital, 
      Rubenacherstr. 170, 56072 Koblenz, Germany.
FAU - Al-Nawas, Bilal
AU  - Al-Nawas B
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, 
      Augustusplatz 2, 55131 Mainz, Germany.
AD  - Platform for Biomaterial Research, BiomaTiCS Group, University Medical Center, 
      Langenbeckstrasse 1, 55131 Mainz, Germany.
FAU - Kammerer, Peer W
AU  - Kammerer PW
AUID- ORCID: 0000-0002-1671-3764
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, 
      Augustusplatz 2, 55131 Mainz, Germany.
AD  - Platform for Biomaterial Research, BiomaTiCS Group, University Medical Center, 
      Langenbeckstrasse 1, 55131 Mainz, Germany.
LA  - eng
GR  - 06/2018/Intramural grant, BiomaTiCS group, University Medical Center Mainz, 
      Germany/
PT  - Journal Article
DEP - 20210110
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC7827266
OTO - NOTNLM
OT  - angiogenesis
OT  - osteogenesis
OT  - platelet-rich fibrin
OT  - tissue engineering
COIS- The authors declare no conflict of interest.
EDAT- 2021/01/14 06:00
MHDA- 2021/01/14 06:01
PMCR- 2021/01/10
CRDT- 2021/01/13 01:01
PHST- 2020/12/23 00:00 [received]
PHST- 2021/01/02 00:00 [revised]
PHST- 2021/01/06 00:00 [accepted]
PHST- 2021/01/13 01:01 [entrez]
PHST- 2021/01/14 06:00 [pubmed]
PHST- 2021/01/14 06:01 [medline]
PHST- 2021/01/10 00:00 [pmc-release]
AID - biomedicines9010061 [pii]
AID - biomedicines-09-00061 [pii]
AID - 10.3390/biomedicines9010061 [doi]
PST - epublish
SO  - Biomedicines. 2021 Jan 10;9(1):61. doi: 10.3390/biomedicines9010061.